FDA vaccine advisers to meet in March on flu strain selection
Tweet
Share
E-mail
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
Feb 25 (Reuters) - The U.S. Food and Drug Administration said on Wednesday its advisory committee is set to meet on March 12 to discuss and make recommendations on the strain composition of flu vaccines for use during the 2026-2027 season.
* Last year, the meeting was canceled, one of manydisruptions to vaccine-related advisory panels under healthsecretary Robert F. Kennedy Jr. * Kennedy, a longtime vaccine skeptic, has overseen sweepingrestructurings at the FDA and CDC, moves that have resulted inthe removal of multiple senior public‑health officials andcareer scientists. * Public health experts and lawmakers raised concerns aboutthe cancellation, which was unusual for the annual process thathelps manufacturers prepare for the next flu season. * Instead of holding the usual public advisory panel vote,the FDA made the strain selection internally and issuedrecommendations directly to manufacturers. * The committee advises the FDA by reviewing vaccine safetyand effectiveness data and recommending whether vaccines shouldbe approved, updated, or modified.(Reporting by Christy Santhosh and Padmanabhan Ananthan in Bengaluru; Editing by Alan Barona)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Pfizer-BioNTech XFG-targeted Covid-19 vaccine
- US academic who accused Jason Arday of plagiarism allowed to resume some work
- Serbia's Vucic raps 'uncivilised' UN court over handling of Mladic death
Create E-mail Alert Related Categories
ReutersRelated Entities
AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
